Links überspringen


Andropeak® – clinical studies

Christian P.
Gesundheits - Redakteur

Lesezeit 2 Minuten
Bildquelle: Shutterstock

Dietary supplements and testosterone deficiency:

When advertising dietary supplements, there is often talk of studies, but how meaningful are these studies actually? First and foremost, one should pay attention to whether the study examined the actual product or only a “similar” product or one with the same main active ingredient but different overall formulation. The exact formulation is very important when it comes to the overall effect of the preparation, as well as the health safety, because different ingredients can affect each other. Especially with only online available dietary supplements, from dubious suppliers should be careful.

Andropeak® has been tested in several studies not only for safety, but its positive effect on testosterone levels. In the following text, we would like to present 3 of these studies in more detail. First of all, we need to start with a brief explanation that should sound familiar to attentive readers of our blog.

Even though people are said to have a testosterone or androgen deficiency, the assumption that the total amount of testosterone in the body would decrease significantly is incorrect. The amount of testosterone in the body usually remains relatively the same. With increasing age, however, more and more is bound to the body’s own protein and is therefore no longer bioavailable. Andropeak® can dissolve out some of this testosterone, significantly increasing the amount effectively available to the body.

When determining the testosterone level (by taking a blood sample), it is essential to specifically request the measurement of total testosterone and free testosterone, as otherwise only the total value is measured, which, however, has little significance for the reasons mentioned above.


Studies on Andropeak®

In March 2009, INDUS Biotech, a biotechnology company with 72 publications in peer-reviewed scientific journals, conducted 2 clinical studies and one preclinical study. The first two clinical studies were, on the one hand, to determine the bioavailable testosterone levels and, on the other hand, on the influence of Andropeak® on the physique. Both studies were double-blind, randomized trials with a placebo control group. The 3rd study was an evaluation of health safety.

In the first study, 16 healthy volunteers were administered a daily dose of Andropeak®. Total testosterone levels and free and bioavailable testosterone levels were measured immediately before ingestion, after ingestion, and 3, 7, and 12 hours later.

  • After 12 hours, the level of total testosterone increased by 31% compared to a 12% increase with the placebo.
  • Durch die direkte Messmethode stieg die Menge an freiem Testosteron im Körper um 20,3 %, anstatt um 1 % mit dem Placebo, was bedeutet, dass die Wirkung von Andropeak® 20 Mal größer ist als die eines Placebos.
  • In the indirect measurement method, which has a higher accuracy, the increase in free testosterone is 43%.
  • The amount of bioavailable testosterone is obtained by adding the free testosterone + the testosterone weakly bound to albumin (a protein). Bioavailable testosterone increased by 37% with Andropeak®, compared to 15.1% with placebo.
  • Bioavailable testosterone, as the name suggests, is available to the body for physiological functions.


Die 2. Studie war eine doppelblinde, placebokontrollierte, prospektive Studie. The study had 60 participants and spanned a period of 8 weeks. Participants had one hour of training a day, 5 days a week and received a daily dose of Andropeak®. The factors to be evaluated were intake of nitrogen and variance in body composition and muscle mass; improved intake of nitrogen promotes muscle formation. The study concluded the following:

  • Andropeak® increases lean muscle mass without an increase in weight. There was a 13 percent decrease in skinfold thickness (fat percentage), with no change in weight. Decrease in skinfold thickness of the triceps (14.5%) and thighs (12.6%) without an increase in body weight. This confirms a more beneficial body composition.
  • Treatment with Andropeak® resulted in a positive nitrogen balance. Increased skeletal muscle nitrogen uptake was seen, an indicator of the anabolic activity of Andropeak(Important: Anabolic refers to the build-up of endogenous substances and has nothing to do with doping!).


The 3rd study addressed the safety and health safety of Andropeak®. No adverse health effects were found. Andropeak® was assessed as safe in all parameters studied.



  1. Andropeak® – Product Monograph – INDUS Biotech (2009).
  2. Abdel-Barry, J. A., Abdel-Hassan, I. A. and Al-Hakiem, M. H. (1997). Hypoglycaemic and antihyperglycaemic effects of Trigonella foenum-graecum leaf in normal and alloxan induced diabetic rats. J Ethnopharmacol 58(3): 149-55.
  3. Al-Meshal, I. A., Parmar, N. S., Tariq, M. and Aqeel, A. M. (1985). Gastri anti-ulcer activity in rats of Trigonella foenum-graecum (HU-Lu-Pa). Fitoterapia 56: 232-235.
  4. American Diabetes Association (2008). Standards of medical care in diabetes – 2008. Diabetes Care 31 Suppl 1:S12-54.
  5. Bolen, S., Feldman, L., Vassy, J., Wilson, L., Yeh, H. C., Marinopoulus, S., Wiley, C., Selvin, E., Wilson, R., Bass, E. B. and Brancati, F. L. (2007). Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Annals of Internal Medicine 147(6): 386-99.
  6. Bordia, A., Verma, S. K. and Srivastava, K. C. (1997). Effect of ginger (Zingiber officinale Rosc.) and fenugreek (Trigonella foenum-graecum L.) on blodd lipids, blood sugar and platelet aggregation in patients with coronary artery disease. Prostaglandins Leukot Essent Fatty Acids 56(5): 379-84.
  7. Derosa, G. and Sibilla, S. (2007). Optimizing combination treatment in the management of type 2 diabetes. Vasc Health Risk Manag 3(5): 665-71.
  8. DiPiro, J. T. (2005). Pharmacotherapy: a pathophysiologic approach. London, McGraw-Hill.
  9. Gupta, A., Gupta, R. and Lal, B. (20021). Effect of Trigonella foenum-graecum (fenugreek) seeds on glycaemic control and insulin resistance in type 2 diabetes mellitus: a double blind placebo controlled study. J Assoc Physicians India 49: 1057-61.
  10. Javan, M., Ahmadiani, A., Semnanian, S. and Kamalinejad, M. (1997). Antinociceptive effects of Trigonella foenum-graecum leaves extract. J Ethnopharmacol 58(2): 125-9.
  11. Kilo, C., Mezitis, N., Jain, R., Mersey, J., McGill, J. and Raskin, P. (2003). Starting patients with type 2 diabetes on insulin therapy using once-daily injections of biphasic insulin aspart 70/30, biphasic human insulin 70/30, or NPH insulin in combination with metformin. Journal of Diabetes and Its complications 17(6): 307-13.
  12. Madar, Z., Abel, R., Samish, S. and Arad, J. (1988). Glucose-lowering effect of fenugreek in non-insulin dependent diabetics. European Journal of Clinical Nutrition 42(1): 51-4.
  13. Nathan, D. M., Buse, J. B., Davidson, M. B., Heine, R. J., Holman, R. R., Sherwin, R. and Zinman, B. (2006). Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustement of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 29(8): 1963-72.
  14. Sharma, R. D., Raghuram, T. C. and Rao, N. S. (1990). Effect of fenugreeak on blodd glucose and seru lipids in type 1 diabetes. Eur J Clin Nutr 44(4): 301-6.
  15. Stumvoll, M., Nurjhan, N., Perriello, G., Dailey, G. and Gerich, J. E. (1995). Metabolic effects of metformin in non-insulin-dependant diabetes mellitus. New England Journal of Medicine 333(9): 550-4.
  16. UK Prospective Diabetes Study (UKPDS) Group (1998). Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352(9131): 854-65.